What is William Blair’s Estimate for Qiagen FY2024 Earnings?

Qiagen (NYSE:QGEN) – Equities researchers at William Blair increased their FY2024 earnings per share estimates for Qiagen in a research report issued on Monday, November 11th. William Blair analyst A. Brackmann now anticipates that the company will post earnings of $2.17 per share for the year, up from their prior estimate of $2.14. The consensus estimate for Qiagen’s current full-year earnings is $2.18 per share. William Blair also issued estimates for Qiagen’s Q2 2025 earnings at $0.57 EPS, Q3 2025 earnings at $0.58 EPS and FY2025 earnings at $2.26 EPS.

QGEN has been the subject of several other reports. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a research report on Thursday, October 17th. Finally, Robert W. Baird increased their price target on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $50.88.

Qiagen Stock Performance

NYSE:QGEN opened at $42.09 on Wednesday. The firm has a market capitalization of $9.61 billion, a P/E ratio of 107.92, a P/E/G ratio of 3.29 and a beta of 0.41. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44. The company has a fifty day moving average of $43.91 and a 200-day moving average of $43.76. The company has a quick ratio of 1.46, a current ratio of 2.17 and a debt-to-equity ratio of 0.39.

Institutional Trading of Qiagen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. PDT Partners LLC boosted its position in shares of Qiagen by 77.1% during the third quarter. PDT Partners LLC now owns 104,424 shares of the company’s stock valued at $4,759,000 after buying an additional 45,449 shares during the last quarter. Verition Fund Management LLC bought a new position in Qiagen during the 3rd quarter valued at $1,169,000. Capstone Investment Advisors LLC purchased a new position in Qiagen during the 3rd quarter worth $395,000. Public Sector Pension Investment Board grew its stake in shares of Qiagen by 23.7% in the 3rd quarter. Public Sector Pension Investment Board now owns 115,032 shares of the company’s stock worth $5,232,000 after acquiring an additional 22,039 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Qiagen by 44.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 218,127 shares of the company’s stock valued at $9,852,000 after purchasing an additional 67,143 shares during the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.